Evidence map›Paper›PMID 36613466›Full record

ArticleInternational journal of molecular sciences2022

Detection of Circulating Tumor Cells Using the Attune NxT.

Mandy Gruijs, Carolien Zeelen, Tessa Hellingman, Jasper Smit, Frank J Borm, Geert Kazemier, Chris Dickhoff, Idris Bahce, Joop de Langen, Egbert F Smit and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mandy GruijsAmsterdam UMC location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.ORCID 0000-0003-1965-1500
Carolien ZeelenAmsterdam UMC location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
Tessa HellingmanCancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam 1081 HV, The Netherlands.
Jasper SmitNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Thoracic Oncology, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
Frank J BormLeiden University Medical Center, Pulmonology, Albinusdreef 2, Leiden 2333 ZB, The Netherlands.
Geert KazemierCancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam 1081 HV, The Netherlands.
Chris DickhoffCancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam 1081 HV, The Netherlands.
Idris BahceCancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam 1081 HV, The Netherlands.
Joop de LangenNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Thoracic Oncology, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
Egbert F SmitLeiden University Medical Center, Pulmonology, Albinusdreef 2, Leiden 2333 ZB, The Netherlands.
Koen J HarteminkNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Surgery, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands.
Marjolein van EgmondAmsterdam UMC location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, De Boelelaan 1117, Amsterdam 1081 HV, The Netherlands.
Amsterdam University Medical Centers · NLOncode Institute · NLThe Netherlands Cancer Institute · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) have been detected in many patients with different solid malignancies. It has been reported that presence of CTCs correlates with worse survival in patients with multiple types of cancer. Several techniques have been developed to detect CTCs in liquid biopsies. Currently, the only method for CTC detection that is approved by the Food and Drug Administration is CellSearch. Due to low abundance of CTCs in certain cancer types and in early stages of disease, its clinical application is currently limited to metastatic colorectal cancer, breast cancer and prostate cancer. Therefore, we aimed to develop a new method for the detection of CTCs using the Attune NxT-a flow cytometry-based application that was specifically developed to detect rare events in biological samples without the need for enrichment. When healthy donor blood samples were spiked with variable amounts of different EpCAM+EGFR+ tumor cell lines, recovery yield was on average 75%. The detection range was between 1000 and 10 cells per sample. Cell morphology was confirmed with the Attune CytPix. Analysis of blood samples from metastatic colorectal cancer patients, as well as lung cancer patients, demonstrated that increased EpCAM+EGFR+ events were detected in more than half of the patient samples. However, most of these cells showed no (tumor) cell-like morphology. Notably, CellSearch analysis of blood samples from a subset of colorectal cancer patients did not detect CTCs either, suggesting that these blood samples were negative for CTCs. Therefore, we anticipate that the Attune NxT is not superior to CellSearch in detection of low amounts of CTCs, although handling and analysis of samples is easier. Moreover, morphological confirmation is essential to distinguish between CTCs and false positive events.

Indexed as

Breast NeoplasmsColonic NeoplasmsNeoplastic Cells, CirculatingRectal NeoplasmsBiomarkers, TumorCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsHumansMaleBiomarkers, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorscancerCTCCTC detection methodflow cytometrymetastasiswhole blood

Identifiers

PMID36613466
PMCPMC9820284
OpenAlexW4313435891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.